Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing.
Vetter
Victoria L
VL
Elia
Josephine
J
Erickson
Christopher
C
Berger
Stuart
S
Blum
Nathan
N
Uzark
Karen
K
Webb
Catherine L
CL
D000293:Adolescent; D000572:American Heart Association; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy / Q000503:physiopathology; D002318:Cardiovascular Diseases / Q000139:chemically induced / Q000188:drug therapy / Q000503:physiopathology; D000697:Central Nervous System Stimulants / Q000009:adverse effects*; D002648:Child; D006287:Health Planning Guidelines; D006330:Heart Defects, Congenital / Q000188:drug therapy / Q000503:physiopathology; D006331:Heart Diseases / Q000139:chemically induced / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D008991:Monitoring, Physiologic / Q000592:standards; D009729:Nursing / Q000592:standards; D014481:United States
D000697:Central Nervous System Stimulants